In the market, vague and unconfirmed rumours were doing the rounds that drug group GlaxoSmithKline PLC (LON:GSK) could be among potential bidders for US rival Pacific Biosciences of California (NASDAQ: PACB).
Pacific’s shares have risen about 13% in the last month and were up 2.26% to US$9.95 in early Wall Street trading on Thursday.
Gossips reckoned Swiss group Roche had taken on advisers Greenhill to assess a possible approach, while Pacific was rumoured to have appointed Goldman Sachs to advise on any interest.
PACB partners with IMEC(Belgium) to develop their prototype ZMW, IMEC partners with MOSIS (Los Angeles) for prototype production. MOSIS partners with TSMC and Globalfoundries for large scale production.